pISSN 2508-6235 eISSN 2508-7576

Download original image
Fig. 2. Placebo-subtracted mean weight loss (%) in overweight/obese individuals in clinical trials. All data are placebo-subtracted, maximal dose, intention to treat, last observation carried forward, 1 year, unless otherwise indicated. *Lorcaserin withdrawn from market due to cancer risk. XENDOS, Xenical in the prevention of diabetes in obese subjects11; BLOOM, behavioral modification and lorcaserin for overweight and obesity management15; BLOSSOM, behavioral modification and lorcaserin second study for obesity managementbehavior16; BLOOM-DM, behavioral modification and lorcaserin for overweight and obesity management in diabetes mellitus17; COR-I, the Contrave obesity research-I study18; COR-II, the Contrave obesity research-II study19; COR-BMOD, the Contrave obesity research-intensive behavior modification study20; SCALE, satiety and clinical adiposity–liraglutide21; EQUIP, controlled-release phentermine/topiramate in severely obese adults22; CONQUER, effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults.23
J Obes Metab Syndr 2020;29:99~109 https://doi.org/10.7570/jomes20010